SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, in patients with advanced solid tumors.
“HER3 is a key dimerization partner of EGFR, and their interaction is known to drive oncogenic signaling across a range of solid tumors, including non-small cell lung cancer, breast cancer, and head and neck cancer,” said Anthony Tolcher, M.D., FRCPC, CEO and Founder, NEXT Oncology. “Based on its preclinical data and differentiated design targeting this pathway, AVZO-1418 offers a promising approach for patients with advanced solid tumors.”
The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418 as a single agent and in combination therapy in patients with advanced solid tumors.
“We are excited to have initiated our company’s second clinical trial within 2 weeks of receiving IND clearance,” said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. “This is another important milestone in our journey to advance potentially differentiated drug candidates that help fight cancers with high unmet medical needs.”
About Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs). Avenzo’s small molecule inhibitors, AVZO-021 and AVZO-023, are novel, highly potent and selective inhibitors of CDK2 and CDK4, respectively, which are key enzymes involved in cell cycle regulation. AVZO-021, the company’s lead drug candidate, is being studied in a Phase 1 study in the U.S. and Australia for the treatment of advanced solid tumors and in combinations in HR+/HER2- metastatic breast cancer. The company plans to initiate a Phase 1/2 study for AVZO-023 in the third quarter of 2025 in patients with advanced or metastatic HR+/HER2- breast cancer and other advanced solid tumors. Avenzo’s first ADC drug candidate, AVZO-1418, is a potential best-in-class, novel EGFR/HER3 bispecific ADC that is being studied in a Phase 1/2 study for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California. For more information, visit us at www.avenzotx.com or on LinkedIn.
Contacts
Avenzo Therapeutics Contact:
Carla Taub
Media Relations
ctaub@avenzotx.com
